Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelinesLeticia Monin, Sheeba Irshad, Miguel Muñoz‐Ruiz et al.|medRxiv|2021Cited by 61